Optimizing outcomes in depression: Focus on antidepressant compliance

International Clinical Psychopharmacology

Volumn 17, Issue 6, 2002, Pages 265-271

  Keller, Martin B ^a   Hirschfeld, R M A ^a   Demyttenaere, K ^a   Baldwin, D S ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Depression; Efficacy; Selective noradenaline reuptake inhibitor; Selective serotonin reuptake inhibitors; Social functioning; Tolerability; Treatment compliance; Tricyclic antidepressants

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; FLUOXETINE; MIRTAZAPINE; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANXIETY; APPETITE DISORDER; BODY WEIGHT DISORDER; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DISEASE EXACERBATION; DROWSINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HUMAN; HYPERHIDROSIS; HYPOTENSION; INSOMNIA; MEDICAL EDUCATION; NAUSEA; NERVOUSNESS; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PSYCHOSIS; RECURRENT DISEASE; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL INTERACTION; TACHYCARDIA; URINARY HESITANCY; VERTIGO; WEIGHT GAIN; XEROSTOMIA;

EID: 0036841082     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200211000-00001     Document Type: Review

References (46)

1. Altamura AC, Mauri M (1985) Plasma concentrations, information and therapy adherence during long-term treatment with antidepressants. Br J Clin Pharmacol 20:714-716.
2. Anderson IM (1998) SSRIs versus tricyclic antidepressants in depressed inpatients: A meta-analysis of efficacy and tolerability. Depress Anxiety 7(Suppl. 1):11-18.
3. Anderson IM, Tomenson BM (1995) Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: A meta-analysis. BMJ 310:1433-1438.
4. Andrews JM, Ninan PT, Nemeroff CB (1996) Venlafaxine: A novel antidepressant that has a dual mechanism of action. Depression 4:48-56.
5. Blackwell B (1976) Treatment adherence. Br J Psychiatry 129:513-531.
6. Cookson J (1993) Side-effects of antidepressants. Br J Psychiatry 163:20-24.
7. Demyttenaere K (1997) Compliance during treatment with antidepressants. J Affect Disord 43:27-39.
8. Demyttenaere K (1998) Noncompliance with antidepressants; who's to blame? Int Clin Psychopharmacol 13:S19-S25.
9. Demyttenaere K, Van Ganse E, Gregoire J, Gaens E, Mesters P. (1998) Compliance in depressed patients treated with fluoxetine or amitriptyline. Int Clin Psychopharmacol 13:11-17.
10. DiMatteo MR, Lepper HS, Croghan TW (2000) Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 160:2101-2107.
11. Entsuah AR, Rudolph RL, Hackett D, Miska S. (1996) Efficacy of venlafaxine and placebo during long-term treatment of depression: A pooled analysis of relapse rates. Int Clin Psychopharmacol 11:137-145.
12. Fawcett J (1995) Compliance: definitions and key issues. J Clin Psychiatry 56:4-8.
13. Feighner JP (1994) Compliance and quality of response are major contributors to cost-effective antidepressant therapy. Hum Psychopharmacol 9:S21-S23.
14. Frank E (1997) Enhancing patient outcomes: Treatment adherence. J Clin Psychiatry 58:11-14.
15. Frank E, Perel JM, Mallinger AG, Thase ME, Kupfer DJ. (1992) Relationship of pharmacologic compliance to long-term prophylaxis in recurrent depression. Psychopharmacol Bull 28:231-235.
16. Frank E, Kupfer DJ, Siegel LR (1995) Alliance not compliance: A philosophy of outpatient care. J Clin Psychiatry 56(Suppl. 1):11-17.
17. Frazer A (1997) Antidepressants. J Clin Psychiatry 58(Suppl. 6):9-25.
18. George CF, Peveler RC, Heiliger S, Thompson C (2000) Compliance with tricyclic antidepressants: The value of four difference methods of assessment. Br J Clin Pharmacol 50:166-171.
19. Gitlin MJ, Cochran SD, Jamison KR (1989) Maintenance lithium treatment: Side effects and compliance. J Clin Psychiatry 50:127-131.
20. Guze SB, Robins E (1970) Suicide and primary affective disorders. Br J Psychiatry 117:437-438.
21. Jacob M, Frank E, Kupfer DJ, et al. (1987) A psychoeducational workshop for depressed patients, family and friends: Description and evaluation. Hosp Commun Psychiatry 38:968-972.
22. Johnson DAW (1981) Depression: Treatment compliance in general practice. Acta Psychiatr Scand 63:447-453.
23. Johnson DAW (1986) Non-compliance with antidepressant therapy - An underestimated problem. Intern Med 11:14-17.
24. Katon W, Von Korf M, Lin E, Walker E, Simon GE, Bush T., et al. (1995) Collaborative management to achieve treatment guidelines. Impact on depression in primary care. JAMA 273:1026-1031.
25. Keller MB (1990) Depression: Underrecognition and undertreatment by psychiatrists and other healthcare professionals. Arch Intern Med 150:946-948.
26. Keller MB, Boland RJ (1998) Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. Biol Psychiatry 44:348-360.
27. Keller MB, Klerman GL, Lavori PW, Coryell W, Endicott J, Taylor J. (1984) Long-term outcome of episodes of major depression: Clinical and public health significance. JAMA 252:788-792.
28. Keller MB, Lavori PW, Mueller TI, Endicott J, Coryell W, Hirschfeld RM, Shea T. (1992) Time to recovery, chronicity and levels of psychopathology in major depression: A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 49:809-816.
29. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51:8-19.
30. Kirscht JP, Rosenstock IM (1979) Patients' problems in following the recommendation of health experts. In: Health Psychology (Stone GC, Cohen F, Adler ME, eds.), San Francisco: Jossey-Bass, pp. 189-215.
31. MacDonald TM, McMahon AD, Reid IC, Fenton GW, McDevitt DG. (1996) Antidepressant drug use in primary care: A record linkage study in Tayside, Scotland. BMJ 313:860-861.
32. Maddox JC, Levi M, Thompson C (1994) The compliance with antidepressants in general practice. J Psychopharmacol 8:48-53.
33. Melfi CA, Chawla AJ, Croghan TW, Hanna MP, Kennedy S, Sredl K. (1998) The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 55:1128-1132.
34. Montgomery SA, Kasper S (1995) Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: A meta-analysis. Int Clin Psychopharmacol9 (Suppl. 4):33-40.
35. Montgomery SA, Henry J, McDonald G, Dinan T, Lader M, Hindmarch I, Clare A, Nutt D. (1994) Selective serotonin reuptake inhibitors: Meta-analysis of discontinuation rates. Int Clin Psychopharmacol 9:47-53.
36. Montgomery SA, Reimitz PE, Zivkov M (1998) Mirtazapine vs. amitriptyline in the long-term treatment of depression: A double-blind-controlled study. Int Clin Psychopharmacol 13:63-73.
37. Mucci M (1997) reboxetine: A review of antidepressant tolerability. J Psychopharmacol 11:S33-S37.
38. Myers ED, Branthwaite A (1992) Out-patient compliance with antidepressant medication. Br J Psychiatry 160:83-86.
39. Perel JM (1988) Compliance during tricyclic antidepressant therapy: Pharmacokinetic and analytical issues. Clin Chem 34:881-887.
40. Roose SP (1999) Tolerability and patient compliance. J Clin Psychiatry 60:14-17.
41. Rush AJ, Thase ME (1997) Strategies and tactics in the treatment of chronic depression. J Clin Psychiatry 58:14-22.
42. Shaw E (1986) Lithium noncompliance. Psychiatr Ann 16:583-588.
43. Stahl SM, Mendels J, Schwartz GE (2002) Effects of reboxetine on agitation, anxiety, and insomnia: Results of a pooled evaluation of randomised clinical trials. J Clin Psychopharmacol 22:388-392.
44. Stokes PE (1993) Fluoxetine: A five-year review. Clin Ther 15:216-243.
45. Tollefson GD (1993) Adverse drug reactions/interactions in maintenance therapy. J Clin Psychiatry 54:48-58.
46. Wells KB, Stewart A, Hays RD, Burnam MA, Rogers W, Daniels M., et al. (1989) The functioning and well-being of depressed patients: Results of the medical outcomes study. JAMA 262:914-919.